Fluorine F 18 Flotufolastat

Phase 2Small molecule

JJonsson Comprehensive Cancer Center

Fluorine F 18 Flotufolastat is one of 23 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Mekinist

Novartis

Preclinical

3 2

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 3

Viagra

VViatris Specialty LLC

Preclinical

1 4

Duragesic

CCephalon

Preclinical

1 5

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 6

Prednisone/prednisolone

Roche

Preclinical

3 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

—8

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—9

Naropin

FFresenius Kabi Oncology Ltd.

Statin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2036

Phase 2Recruiting

Prostate Cancer

NCT07185165

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT07185165·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fluorine F 18 Flotufolastat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluorine F 18 Flotufolastat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluorine F 18 Flotufolastat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jonsson Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJonsson Comprehensive Cancer Center

Fluorine F 18 Flotufolastat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2036

Trials by Indication[1]

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News